- Breast cancer
- Inflammatory breast cancer
- Invasive breast cancer
- Invasive ductal carcinoma
- Invasive lobular carcinoma
- Local tumor recurrence
- Male breast cancer
- Triple negative breast cancer
- Triple positive breast cancer
Angela DeMichele, MD, MSCE
About me
- Co-Leader, Breast Cancer Research Program
- Co-Director, 2-PREVENT Breast Cancer Translational Center of Excellence
- Mariann T. and Robert J. MacDonald Professor in Breast Cancer Care Excellence
Dr. DeMichele specializes in developing new therapies for breast cancer, neoadjuvant therapy and preventing breast cancer recurrence.
Co-Chair of the ECOG/ACRIN Cooperative Group Breast Committee; Chair, Trial Operations Working Group, I-SPY Consortium; Member of the NCI Breast Cancer Steering Committee
My education and training
- Medical School: Washington University School of Medicine
- Residency: University of Pennsylvania Health System
- Fellowship: University of Pennsylvania Health System
Spoken languages
Reviews
301 reviews
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Insurance accepted
- Aetna Advantra Cares D-SNP
- Aetna Advantra Credit Value
- Aetna Advantra Eagle HMO
- Aetna Advantra Eagle POS
- Aetna Advantra Premier Plus PPO
- Aetna Advantra Value
- Aetna Advantra Value Plus
- Aetna APCN Plus (Multi-Tier)
- Aetna Better Health Kids (CHIP) - DH Only
- Aetna Flexible Five
- Aetna Freedom Core
- Aetna Gold
- Aetna HMO
- Aetna Philly Prime
- Aetna POS
- Aetna PPO APCN
- Aetna Premier
- Aetna Premier Plus
- Aetna Savings Plus
- Aetna Signature Administrators
- Aetna Student Health Plan PPO
- Aetna Upfront Advantage
- First Health HMO
- First Health POS
- First Health PPO
- Meritain - Aramark (Other)
- Meritain - Aramark (Pennsylvania Premier Medical Plan)
- Americhealth Caritas of PA VIP - LGH Only
- Amerihealth Caritas (Transplant patients only)
- Amerihealth Caritas of PA - LGH Only
- Centivo EPO
- Cigna Healthcare EPO
- Cigna Healthcare HMO
- Cigna Healthcare POS
- Cigna Healthcare PPO
- Claim Watcher (Homestead/ INDECs) Open Access
- Clover Health Choice
- Clover Health Choice Value PPO
- Clover Health Classic HMO
- Clover Health Value
Locations
Penn Medicine hospital privileges
- Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Qualifications and experience
- Medical Oncology, 1998
- American Association of Cancer Research (AACR), National
- American Board of Internal Medicine (ABIM), National
- American College of Epidemiology, National
- American College of Physicians, National
- American Society of Breast Disease, National
- American Society of Clinical Oncology (ASCO), National
- College of Physicians, National
- Common Sense Oncology, International
- European Society of Clinical Oncology, International
- Living Beyond Breast Cancer, National
- National Comprehensive Cancer Network (NCCN), National
- St. Gallen International Consensus, International
- Penn Breast Cancer Program
- Recognized annually in Philadelphia Magazine's Top Docs issue from 2018 through 2025
Treatments and conditions
Research
Publications
DeMichele A, Clark AS, Shea E, Bayne LJ, Sterner CJ, Rohn K, Dwyer S, Pan TC, Nivar I, Chen Y, Wileyto P, Berry LR, Deluca S, Savage J, Makhlin I, Pant DK, Martin H, Egunsola A, Mears N, Goodspeed BL, Chislock EM, Graves J, Wang J, Shih N, Belka GK, Berry D, Nayak A, Feldman M, Chodosh LA. Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial , Nat Med, 31(10): 2025,3464-3474
Metzger O, Mandrekar S, Goel S, Gligorov J, Lim E, Ciruelos E, Loibl S, Dockter T, Gonzàlez Farré X, Francis PA, Lynce F, Lanzillotti J, DuFrane C, Wall A, Strand C, Krop I, Vaz-Luis I, Tripathy D, Loi S, Prat A, Goetz M, Escrivá-de-Romaní S, Porter D, Spoenlein J, Stover DG, Sardesai S, Heudel P, Koehler M, Huang Bartlett C, Holynskyj A, Gopalakrishna P, Gauthier E, Delaloge S, Miller K, Winer EP, Gianni L, Partridge AH, DeMichele A, Carey LA. Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer , N Engl J Med, 394(5): 2026,451-462
Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Forero-Torres A, Elias A, Lang JE, Ellis ED, Yung R, Tripathy D, Nanda R, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA, Alvarado M, Crane EP, Buxton M, Clennell JL, Paoloni M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Melisko M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hylton NM, Berry DA, Esserman LJ, DeMichele AM Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2-positive breast cancer in the adaptively randomized I-SPY2 trial: Efficacy and biomarkers , Nat Commun, 12(1): 2021,6428
Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, Fox P, Wolff A C, Chan A, Winer EP, Pfeiler G, Miller KD, Colleoni M, Suga J M, Rubovsky G, Bliss JM, Mayer, IA, Singer CF, Nowecki Z, Hahn O, Thomson J, Wolmark N, Amillano K, Rugo HS, Steger GG, Aranguiz B, Hadad T, Perello A, Bellet M, Fohler H, Filho O, Halper A, Solomon K, Schurmans C, Theall KP, Lu DR, Tenner K, Fesl K, DeMichele A, Mayer E, PALLAS groups and investigators Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) , J Clin Oncol, 40(3): 2022,282-293
Gerratana L, Reduzzi C, Ren Y, Jeselsohn R, Mahtani RL, Ma CX, DeMichele A, Meisel JL, Miller K, Abdou Y, Riley EC, Qamar R, Sharma P, Reid SA, Ko N, Liu Y, Gauthier E, Burstein HJ, DeMeo M, Tolaney SM, Regan MM, Cristofanilli M, Mayer EL. Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study. , Clin Cancer Res, 31(21): 2025,4510-4517
Magbanua MJM, Manon NA, Wolf DM, Rivero-Hinojosa S, Ahmed Z, Sayaman RW, Tin A, Renner D, Kalashnikova E, Brown-Swigart L, Hirst GL, Yau C, Li W, Isaacs C, Shatsky RA, Clark AS, Zimmer A, Delson AL, Rodriguez A, Liu MC, Pohlmann PR, Esserman LJ, Rugo HS, DeMichele A, van 't Veer L. Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors. , Nat Commun, 16(1): 2025,9945
Chislock EM, Pan TC, Pant D, Chen Y, Woodfield G, Graves J, Lawrence-Paul MR, Belka GK, Wang J, Bayne L, Blanchard T, Smith M, Ji X, Shih NNC, Soucier-Ernst D, Goodman N, Nivar I, Goodspeed B, DeLuca S, Ndicu J, Clark C, Langer M, William Stavropoulos S, DeMuth W, Morschauser A, Murphy W, Nayak A, Feldman M, Clark A, Yu L, Judge K, Bornheimer S, Pletcher CH Jr, Moore JS, DeMichele A, Chodosh LA. DTC-Flow: a flow cytometry-based detection platform for characterizing bone marrow disseminated tumor cells in breast cancer , NPJ Breast Cancer , 11(1): 2025,139
Sun X, Ocampo AA, Hanna A, Taylor BC, Marshall JL, Steele JA, Axelrod ML, Wescott EC, Opalenik SR, DeMichele A, Esserman LJ, Liu MC, Nanda R, Wolf DM, Brown Swigart L, Hirst GL, van 't Veer LJ, Xu Y, Balko JM. Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer , Sci Transl Med, 18(846): 2026
Hunter NB, Parsons HA, Cope L, Canzoniero JV, Navarro FCP, El-Refai S, Anampa JD, Sparano JA, Rimawi M, Storniolo AM, Mainor C, Nanda R, DeMichele A, Gupta GP, Stringer-Reasor EJ, Lynce F, Cobain EF, Puhalla S, Jankowitz R, Rexer B, Mayer I, Hwang ES, Blackwell K, El Ayass W, Lee Y, Tweed C, Wilkinson M, Pennisi A, Sun B, Wright P, Gralow JR, Chen R, Boyle SM, Stearns V, Wolff AC, Park BH. The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease , J Clin Oncol, 44(14): 2026,1283-1295
Forster M, Zhao F, Bell S, Mayer IA, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Brown-Glaberman U, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Carlos RC, Wolff AC, Miller KD, Reid S. Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 Trial , JCO Oncol Adv, 3(2): 2026,e2500177
